The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
Open accessAbstract
Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients with NSCLC and have led to unprecedented improvements in response rates and survival in a subset of patients with this fatal disease. However, the available therapies work only for a minority of patients, are associated with substantial societal cost, and may lead to considerable immune-related adverse events. Therefore, patient selection must be optimized through the use of relevant biomarkers. Programmed death-ligand 1 protein expression by immunohistochemistry is widely used today for the selection of programmed cell death protein 1 inhibitor therapy in patients with NSCLC; however, this approach lacks robust sensitivity and specificity for predicting response. Tumor mutation burden (TMB), or the number of somatic mutations derived from next-generation sequencing techniques, has been widely explored as an alternative or complementary biomarker for response to ICIs. In theory, a higher TMB increases the probability of tumor neoantigen production and therefore, the likelihood of immune recognition and tumor cell killing. Although TMB alone is a simplistic surrogate of this complex interplay, it is a quantitative variable that can be relatively readily measured using currently available sequencing techniques. A large number of clinical trials and retrospective analyses, employing both tumor and blood-based sequencing tools, have evaluated the performance of TMB as a predictive biomarker, and in many cases reveal a correlation between high TMB and ICI response rates and progression-free survival. Many challenges remain before the implementation of TMB as a biomarker in clinical practice. These include the following: (1) identification of therapies whose response is best informed by TMB status; (2) robust definition of a predictive TMB cut point; (3) acceptable sequencing panel size and design; and (4) the need for robust technical and informatic rigor to generate precise and accurate TMB measurements across different laboratories. Finally, effective prediction of response to ICI therapy will likely require integration of TMB with a host of other potential biomarkers, including tumor genomic driver alterations, tumor-immune milieu, and other features of the host immune system. This perspective piece will review the current clinical evidence for TMB as a biomarker and address the technical sequencing considerations and ongoing challenges in the use of TMB in routine practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Self-citationMolecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 12×
“As a proxy for neoantigen load, usually only nonsynonymous point mutations that cause amino acid substitutions in the resulting proteins are included in the TMB count.30 Splice site and small insertion-deletion (indel) mutations may be included variably in calculations of TMB, and some investigators have begun investi…”
InfluentialSelf-citationTumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063 · cited 1×
“On the basis of CheckMate 568, a prespecified TMB cutoff of 10 mutations per Mb was selected for CheckMate 227, which assessed PFS with low-dose ipilimumab plus nivolumab versus chemotherapy in patients with high TMB, irrespective of PD-L1 expression, as one of two coprimary end points.(33) In the high TMB population,…”
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823
Self-citationNovello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Self-citationFirst-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Self-citationComprehensive genomic profiles of small cell lung cancer
George, J., Lim, J. S., Jang, S. J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X., Fernández-Cuesta, L., Bosco, G., et al. (2015) · Nature · doi:10.1038/nature14664 · Cited by 2,340
Self-citationPan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641
Self-citationRizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367 · cited 2×
“The reliability of ICI response prediction improves when PD-L1 and TMB are combined in a multivariable model.(49,61)”
Self-citationHirsch, F. R., McElhinny, A., Stanforth, D., Ranger-Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D., Vennapusa, B., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2228 · Cited by 1,270
Self-citationGainor, J. F., Shaw, A. T., Sequist, L. V., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,250
Self-citationDistinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Cancer Genome Atlas Research Network, Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., Shukla, S. A., Guo, G., Brooks, A. N., et al. (2016) · Nature Genetics · doi:10.1038/ng.3564 · Cited by 1,200
Garon, E. B., Hellmann, M. D., Rizvi, N. A., Carcereny, E., Leighl, N. B., Ahn, M.-J., Eder, J. P., Balmanoukian, A. S., Aggarwal, C., Horn, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00934 · Cited by 1,163
Gandara, D. R., Paul, S. M., Kowanetz, M., Schleifman, E., Zou, W., Li, Y., Rittmeyer, A., Fehrenbacher, L., Otto, G., Malboeuf, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0134-3 · Cited by 1,157
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142 · cited 1×
“pothesized that zygosity in those genes affects the survival of patients treated with immunotherapy.(90) The”
Self-citationMutational signatures associated with tobacco smoking in human cancer
Alexandrov, L. B., Ju, Y. S., Haase, K., Van Loo, P., Martincorena, I., Nik-Zainal, S., Totoki, Y., Fujimoto, A., Nakagawa, H., Shibata, T., et al. (2016) · Science · doi:10.1126/science.aag0299 · Cited by 1,100
Hellmann, M. D., Nathanson, T., Rizvi, H., Creelan, B. C., Sanchez-Vega, F., Ahuja, A., Ni, A., Novik, J. B., Mangarin, L. M. B., Abu-Akeel, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.018 · Cited by 1,095
Self-citationOtt, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2276 · Cited by 969
Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Al Bakir, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30516-8 · Cited by 911
Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 893
Self-citationTsao, M. S., Kerr, K. M., Kockx, M., Beasley, M.-B., Borczuk, A. C., Botling, J., Bubendorf, L., Chirieac, L., Chen, G., Chou, T.-Y., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.013 · Cited by 794
Self-citationPD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Roemer, M. G. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., Connelly, C. F., Sun, H. H., Daadi, S. E., Freeman, G. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.4482 · Cited by 791
Gettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., Wurtz, A., Dong, W., Cai, G., Melnick, M. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0593 · Cited by 787
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
Razavi, P., Li, B. T., Brown, D. N., Jung, B., Hubbell, E., Shen, R., Abida, W., Juluru, K., De Bruijn, I., Hou, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0652-7 · Cited by 769
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Miao, D., Margolis, C. A., Vokes, N. I., Liu, D., Taylor-Weiner, A., Wankowicz, S. M., Adeegbe, D., Keliher, D., Schilling, B., Tracy, A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0200-2 · Cited by 620
Self-citationTopalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Sosman, J. A., Atkins, M. B., Leming, P. D., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2187 · Cited by 619
Lu, S., Stein, J. E., Rimm, D. L., Wang, D. W., Bell, J. M., Johnson, D. B., Sosman, J. A., Schalper, K. A., Anders, R. A., Wang, H., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1549 · Cited by 607
Lee, C. K., Man, J., Lord, S., Cooper, W., Links, M., Gebski, V., Herbst, R. S., Gralla, R. J., Mok, T., & Yang, J. C.-H. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4427 · Cited by 598
Self-citationReady, N., Hellmann, M. D., Awad, M. M., Otterson, G. A., Gutierrez, M., Gainor, J. F., Borghaei, H., Jolivet, J., Horn, L., Mates, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01042 · Cited by 581
Sunshine, J., & Taube, J. M. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.011 · Cited by 560
A High Frequency of Sequence Alterations Is Due to Formalin Fixation of Archival Specimens
Williams, C., Pontén, F., Moberg, C., Söderkvist, P., Uhlén, M., Pontén, J., Sitbon, G., & Lundeberg, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65461-2 · Cited by 514
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
Camidge, D. R., Doebele, R. C., & Kerr, K. M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0173-9 · Cited by 511
Self-citationMerino, D. M., McShane, L. M., Fabrizio, D., Funari, V., Chen, S.-J., White, J. R., Wenz, P., Baden, J., Barrett, J. C., Chaudhary, R., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000147 · Cited by 507
Self-citationBenayed, R., Offin, M., Mullaney, K., Sukhadia, P., Rios, K., Desmeules, P., Ptashkin, R., Won, H., Chang, J., Halpenny, D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0225 · Cited by 484
Self-citationVanderwalde, A., Spetzler, D., Xiao, N., Gatalica, Z., & Marshall, J. (2018) · Cancer Medicine · doi:10.1002/cam4.1372 · Cited by 458
Büttner, R., Gosney, J. R., Skov, B. G., Adam, J., Motoi, N., Bloom, K. J., Dietel, M., Longshore, J. W., López-Ríos, F., Penault-Llorca, F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7642 · Cited by 397
Self-citationHastings, K., Yu, H. A., Wei, W., Sanchez-Vega, F., DeVeaux, M., Choi, J., Rizvi, H., Lisberg, A., Truini, A., Lydon, C. A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz141 · Cited by 366
Implementing TMB measurement in clinical practice: considerations on assay requirements
Büttner, R., Longshore, J. W., López-Ríos, F., Merkelbach-Bruse, S., Normanno, N., Rouleau, E., & Penault-Llorca, F. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000442 · Cited by 345
Self-citationPD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
Lantuejoul, S., Sound-Tsao, M., Cooper, W. A., Girard, N., Hirsch, F. R., Roden, A. C., Lopez-Rios, F., Jain, D., Chou, T.-Y., Motoi, N., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.107 · Cited by 332
Self-citationOffin, M., Rizvi, H., Tenet, M., Ni, A., Sanchez-Vega, F., Li, B. T., Drilon, A., Kris, M. G., Rudin, C. M., Schultz, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1102 · Cited by 329
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy474 · Cited by 321
Self-citationSun, J. X., He, Y., Sanford, E., Montesion, M., Frampton, G. M., Vignot, S., Soria, J.-C., Ross, J. S., Miller, V. A., Stephens, P. J., et al. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005965 · Cited by 273
Han, J., Duan, J., Bai, H., Wang, Y., Wan, R., Wang, X., Chen, S., Tian, Y., Wang, D., Fei, K., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0398 · Cited by 264
Stenzinger, A., Allen, J. D., Maas, J., Stewart, M. D., Merino, D. M., Wempe, M. M., & Dietel, M. (2019) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22733 · Cited by 239
Duruisseaux, M., Martínez-Cardús, A., Calleja-Cervantes, M. E., Moran, S., Castro de Moura, M., Davalos, V., Piñeyro, D., Sanchez-Cespedes, M., Girard, N., Brevet, M., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30284-4 · Cited by 224
Self-citationPtashkin, R. N., Mandelker, D. L., Coombs, C. C., Bolton, K., Yelskaya, Z., Hyman, D. M., Solit, D. B., Baselga, J., Arcila, M. E., Ladanyi, M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2297 · Cited by 212
Self-citationThe impact of tumor profiling approaches and genomic data strategies for cancer precision medicine
Garofalo, A., Sholl, L., Reardon, B., Taylor-Weiner, A., Amin-Mansour, A., Miao, D., Liu, D., Oliver, N., MacConaill, L., Ducar, M., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0333-9 · Cited by 179
Self-citationSize matters: Dissecting key parameters for panel‐based tumor mutational burden analysis
Buchhalter, I., Rempel, E., Endris, V., Allgäuer, M., Neumann, O., Volckmar, A., Kirchner, M., Leichsenring, J., Lier, A., von Winterfeld, M., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31878 · Cited by 172
Khier, S., & Lohan, L. (2018) · Future Science OA · doi:10.4155/fsoa-2017-0140 · Cited by 165
Shi, M., Roemer, M. G. M., Chapuy, B., Liao, X., Sun, H. H., Pinkus, G. S., Shipp, M. A., Freeman, G. J., & Rodig, S. J. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000297 · Cited by 164
Do, H., & Dobrovic, A. (2012) · Oncotarget · doi:10.18632/oncotarget.503 · Cited by 159
Zhang, J., Ji, Z., Caushi, J. X., Asmar, M. E., Anagnostou, V., Cottrell, T. R., Chan, H. Y., Suri, P., Guo, H., Merghoub, T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2931 · Cited by 157
Negrao, M. V., Lam, V. K. L., Reuben, A., Rubin, M. L., Landry, L. L., Roarty, E. B., Rinsurongkawong, W., Lewis, J., Roth, J. A., Swisher, S. G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.008 · Cited by 126
Self-citationAlborelli, I., Leonards, K., Rothschild, S. I., Leuenberger, L. P., Prince, S. S., Mertz, K. D., Poechtrager, S., Buess, M., Zippelius, A., Laubli, H. P., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5344 · Cited by 125
Self-citationHigh-resolution analysis of the human T-cell receptor repertoire
Ruggiero, E., Nicolay, J. P., Fronza, R., Arens, A., Paruzynski, A., Nowrouzi, A., Ürenden, G., Lulay, C., Schneider, S. O., Goerdt, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9081 · Cited by 122
Stenzinger, A., Endris, V., Budczies, J., Merkelbach‐Bruse, S., Kazdal, D. N., Dietmaier, W., Pfarr, N., Siebolts, U., Hummel, M., Herold, S., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.023 · Cited by 118
Application of Plasma Genotyping Technologies in Non–Small Cell Lung Cancer: A Practical Review
Sacher, A. G., Komatsubara, K. M., & Oxnard, G. R. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.022 · Cited by 104
Paz-Ares, L. G., Langer, C. J., Novello, S., Halmos, B., Cheng, Y., Gadgeel, S. M., Hui, R., Sugawara, S., Borghaei, H., Cristescu, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.078 · Cited by 104
Herbst, R. S., Lopes, G., Kowalski, D. M., Nishio, M., Wu, Y., de Castro, G., Baas, P., Kim, D.-W., Gubens, M. A., Cristescu, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.077 · Cited by 101
Kazdal, D. N., Endris, V., Allgäuer, M., Kriegsmann, M., Leichsenring, J., Volckmar, A., Harms, A., Kirchner, M., Kriegsmann, K., Neumann, O., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.07.006 · Cited by 100
Self-citationRizvi, N. A., Cho, B. C. C., Reinmuth, N., Lee, K. H., Ahn, M., Luft, A. V., van den Heuvel, M. M., Cobo, M., Smolin, A., Vicente, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy511.005 · Cited by 92
Self-citationBeyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer
Voong, K. R., Feliciano, J. L., Becker, D. J., & Levy, B. P. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.48 · Cited by 87
Kowanetz, M., Zou, W., Shames, D. S., Cummings, C. A., Rizvi, N. A., Spira, A. I., Frampton, G. M., Lévêque, V., Flynn, S., Mocci, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.343 · Cited by 86
Rozenblum, A. B., Ilouze, M., Dudnik, E., Dvir, A., Soussan‐Gutman, L., Geva, S., & Peled, N. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.021 · Cited by 84
Gubens, M. A., & Davies, M. J. (2019) · PubMed · doi:10.6004/jnccn.2019.5005 · Cited by 78
Peters, S., Cho, B. C., Reinmuth, N., Lee, K. H., Luft, A. V., Ahn, M., Baas, P., Cobo, M., Smolin, A., Vicente, D., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-ct074 · Cited by 78
Self-citationHu‐Lieskovan, S., Lisberg, A. E., Zaretsky, J. M., Grogan, T., Rizvi, H. A., Wells, D. K., Carroll, J., Cummings, A. L., Madrigal, J., Jones, B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4275 · Cited by 77
Ramalingam, S. S., Hellmann, M. D., Awad, M. M., Borghaei, H., Gainor, J. F., Brahmer, J. R., Spigel, D. R., Reck, M., O'Byrne, K. J., Paz-Ares, L. G., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-ct078 · Cited by 71
Kim, E. S., Velcheti, V., Mekhail, T. M., Leal, T. A. B., Dowell, J. E., Tsai, M. L., Dakhil, C. S. R., Stella, P. J., Shen, V., Hu, S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.067 · Cited by 62
Socinski, M. A., Velcheti, V., Mekhail, T. M., Chae, Y. K., Leal, T. A. B., Dowell, J. E., Tsai, M. L., Dakhil, C. S. R., Stella, P. J., Shen, V., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.081 · Cited by 56
Richard, C., Fumet, J.-D., Chevrier, S., Dérangère, V., Ledys, F., Lagrange, A., Favier, L., Coudert, B. P., Arnould, L., Truntzer, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1940 · Cited by 51
Chaudhary, R., Quagliata, L., Jermann, P. M., Alborelli, I., Cyanam, D., Mittal, V., Tom, W., Au-Young, J. K., Sadis, S. E., & Hyland, F. C. L. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.01 · Cited by 46
Velcheti, V., Kim, E. S., Mekhail, T. M., Dakhil, C. S. R., Stella, P. J., Shen, X., Hu, S., Paul, S. M., Shames, D. S., Yun, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.12001 · Cited by 43
Moens, L., Falk-Sörqvist, E., Ljungström, V., Mattsson, J. S. M., Sundström, M., Fleur, L. L., Mathot, L., Micke, P., Nilsson, M. F., & Botling, J. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.06.009 · Cited by 21
Self-citationFabrizio, D. A., Malboeuf, C. M., Lieber, D. S., Zhong, S., He, J., White, E., Coyne, M. J., Silterra, J., Brennan, T., Ma, J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx363.018 · Cited by 21
Miyauchi, E., Matsuda, T., Kiyotani, K., Low, S., Hsu, Y., Tsukita, Y., Ichinose, M., Sakurada, A., Okada, Y., Saito, R., et al. (2018) · Cancer Science · doi:10.1111/cas.13919 · Cited by 21
Qiu, P., Pang, L., Arreaza, G., Maguire, M. G., Chang, K. C. N., Marton, M. J., & Levitan, D. J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050651 · Cited by 20
Facchinetti, F., Bordi, P., Leonetti, A., Buti, S., & Tiseo, M. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s124380 · Cited by 18
Do, H., Molania, R., Mitchell, P. L., Vaiškunaite, R., Murdoch, J. D., & Dobrovic, A. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.271932 · Cited by 17
Mok, T. S. K., Gadgeel, S. M., Kim, E. S., Velcheti, V., Hu, S., Riehl, T., Schleifman, E., Paul, S. M., Mocci, S., Shames, D. S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx380.084 · Cited by 17
Singal, G., Miller, P. G., Agarwala, V., Li, G., Gossai, A., Albacker, L. A., Goldberg, M. E., He, J., Frank, S., Bourque, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx376.005 · Cited by 12
Cited by
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0013 · Cited by 948
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
Imyanitov, E. N., Iyevleva, A. G., & Levchenko, E. V. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103194 · Cited by 526
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Metadata
- Authors
- Sholl, L. M., Hirsch, F. R., Hwang, D., Botling, J., Lopez-Rios, F., Bubendorf, L., Mino-Kenudson, M., Roden, A. C., Beasley, M. B., Borczuk, A., Brambilla, E., Chen, G., Chou, T.-Y., Chung, J.-H., Cooper, W. A., Dacic, S., Lantuejoul, S., Jain, D., Lin, D., Minami, Y., Moreira, A., Nicholson, A. G., Noguchi, M., Papotti, M., Pelosi, G., Poleri, C., Rekhtman, N., Tsao, M.-S., Thunnissen, E., Travis, W., Yatabe, Y., Yoshida, A., Daigneault, J. B., Zehir, A., Peters, S., Wistuba, I. I., Kerr, K. M., & Longshore, J. W.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 15
- Issue
- 9
- Pages
- 1409-1424
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W3033203711
- Cited by
- 283
- References
- 93
- FWCI
- 14.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.